Jiangsu Recbio Technology Co., Ltd.
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company is developing vaccines for the treatment of cervical cancer and genital…
Biotechnology
CN, Taizhou [HQ]
Ratios
5 Sheets · From 2023 to 2019Configuration
Margins, Growth Rates In %
| Ratio | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross Margin | - - | 100.00 | 100.00 | 100.00 | 73.54 | |
| Profit Margin | - - | -14,480.86 | -11,335.25 | -13,506.10 | -1,882.86 | |
| Operating Margin | - - | -10,128.19 | -9,879.90 | -13,820.94 | -2,033.60 | |
|
EPS Growth
|
- - | -2.33 | -256.82 | 3.19 | 21.71 | |
| EPS CNY | -43.00 | -44.00 | -157.00 | -152.00 | -119.00 | |
| Return on Assets (ROA) | -47.78 | -20.17 | -36.61 | -31.14 | -26.16 | |
| Return on Equity (ROE) | 63.77 | 20.93 | -41.99 | -43.28 | -53.38 | |
| Return on Invested Capital (ROIC) | 34.15 | 17.69 | -37.40 | -36.98 | -35.84 | |
| Solvency | ||||||
| Equity Ratio | - - | - - | - - | - - | - - | |
| Debt/Assets | 1.30 | 2.50 | 4.00 | 12.24 | 29.77 | |
| Debt/Equity | -1.73 | -2.59 | 4.59 | 17.01 | 60.74 | |
| Debt/EBITDA | 75.57 | 244.39 | 187.43 | 150.00 | 32.32 | |
|
Debt/Capitalization
|
-1.76 | -2.66 | 4.38 | 14.53 | 37.79 | |
| Long-Term Debt/Capitalization | -0.76 | -2.21 | 3.95 | 13.57 | 35.50 | |
| Interest Debt per Share CNY | 0.17 | 0.13 | 0.30 | 0.60 | 1.35 | |
| Debt Growth | - - | 372.51 | 193.66 | 268.39 | 130.27 | |
| Liquidity | ||||||
| Current Ratio | 1,745.42 | 1,234.11 | 929.39 | 431.61 | 254.23 | |
| Quick Ratio | 1,704.05 | 1,220.60 | 912.48 | 414.54 | 233.13 | |
| Cash Ratio | 321.60 | 619.02 | 848.97 | 402.80 | 187.96 | |
| Operating Cash Flow Ratio | -700 | -100 | -300 | -100 | -100 | |
| Turnover | ||||||
| Inventory Turnover | - - | - - | - - | - - | 8.57 | |
| Receivables Turnover | - - | 7.35 | 7.15 | 16.17 | 15.64 | |
| Payables Turnover | - - | - - | - - | - - | 6.99 | |
|
Asset Turnover
|
- - | 0.14 | 0.32 | 0.23 | 1.39 | |
| Fixed Turnover | - - | 0.57 | 1.21 | 0.65 | 3.03 | |
| Coverage | ||||||
| Interest Coverage | -95.52 | -397.90 | -1,087.69 | -20,825.27 | - - | |
| Asset Coverage | 7,000 | 3,700 | 2,300 | 600 | 200 | |
| Cash Flow Coverage (CFGR) | -2,507.49 | -269.23 | -616.43 | -205.06 | -98.05 | |
| EBITDA Coverage | - - | -300 | -1,000 | -19,600 | - - | |
| Dividend Coverage | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | |
| Market Prospects | ||||||
| Dividend Yield | - - | - - | - - | - - | - - | |
| Earnings Yield | -1.89 | -2.07 | -7.62 | -6.98 | -12.82 | |
|
Price/Earnings (P/E)
|
-5,302.91 | -4,820.48 | -1,311.80 | -1,432.25 | -780.20 | |
| Price/Earnings Growth (PEG) | - - | -2,072.81 | -5.11 | 449.73 | 35.94 | |
|
Price/Book (P/B)
|
-3,381.85 | -1,008.89 | 550.87 | 619.83 | 416.49 | |
| Price/Tangible Book (P/TB) | -3,381.85 | -1,008.89 | 550.87 | 619.83 | 416.49 | |
| Price/Sales (P/S) | - - | 698,047.53 | 148,695.49 | 193,441.63 | 14,690.12 | |
|
Price/Cash Flow (P/CF)
|
-7,794.77 | -14,469.88 | -1,949.09 | -1,777.40 | -699.36 | |
| Price/Free CF (P/FCF) | -4,966.15 | -4,221.83 | -1,296.82 | -1,159.95 | -517.57 | |
| Price/Operating CF (P/OCF) | -7,794.77 | -14,469.88 | -1,949.09 | -1,777.40 | -699.36 |